Recently, CFDA Southern Medicine Economic Research Institute reported at length on Hansoh pharma's Low-Profile Efforts and Rapid Progress in Top 100 Ranking of Pharmaceutical Industry.
Link address: http://mp.weixin.qq.com/s?__biz=MjM5NzQ4MTg2MQ==&mid=206625599&idx=4&sn=7d76ae8a1eaadbfc6ed9acb7082f6770&scene=2%23rd
Original report:
Hansoh pharma 's Low-Profile Efforts and Rapid Progress in Top 100 Ranking of Pharmaceutical Industry
2014-05-28 MENET
CFDA Southern Medicine Economic Research Institute recently released "Top 100 in China's Pharmaceutical Industry 2013". The list shows that Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ranks 21st, only one step away from the top 20.
Since its ranking among Top 100 in China's Pharmaceutical Industry 2005, the initial release of the list, Hansoh Pharma has been moving all the way up in the ranking after eight years of unremitting innovation and efforts, and has made a "high-profile" appearance in this year's list despite its usual low-profile.
The change in the top 100 list of China's pharmaceutical industry is indeed a microcosm of the development of China's pharmaceutical industry. As an outstanding representative of the top 100, Hansoh Pharma's rapid progress in the ranking reflects that the competition of contemporary pharmaceutical companies has entered a new stage, and they need to identify sustainable competitive advantages as support through R&D innovation and other means.
The development of Hansoh Pharma confirms the importance of innovative R&D to pharmaceutical companies. Founded in 1995, Hansoh Pharma has always attached great importance to R&D investment. The company has established a complete drug R&D system with nearly 1,000 professional and technical personnel and with annual R&D investment exceeding 8% of sales revenue, and has been recognized as a "National Technology Innovation Demonstration Enterprise" by the Ministry of Industry and Information Technology and the Ministry of Finance. In the six major disease fields of anti-tumor, psychiatric, diabetes, cardiovascular, etc., Hansoh Pharma already has nearly 50 varieties that are serving patients. Its gemcitabine hydrochloride won the second prize of National Science and Technology Progress Award; and it has nearly 20 R&D projects included in National Major Scientific and Technological Special Projects of "Significant New Drugs Development". After more than ten years of R&D, two independent innovative drugs of Hansoh Pharma, morinidazole and flumatinib mesylate, have been put on the market; there are also more than ten Class 1.1 innovative drugs under clinical study.
Hansoh Pharma has established a quality control system throughout the process from R&D, production to sales. The process design in accordance with US and EU standards and the use of internationally advanced production equipment and testing instruments ensure controlled quality in the production process and accurate, reliable testing results. All products have passed the new GMP certification, and two anti-tumor injections are among the first to pass the US FDA certification.
The tumor drugs "Zefei", "Pulaile" and "Xinwei", psychotropic drug "Oulanning", diabetes drug "Fulaidi", cardiovascular drug "Zeyue", gastrointestinal drug "Ruibote", and antibiotics "Hengdan" and "Zetan", have all become high-quality brands in the market.
Hansoh Pharma values talents as the most precious strategic resource, and has created a "multi-channel" growth platform and development environment for employees to help them grow along with the company.
In the future, Hansoh Pharma will continue its innovation centered strategy, striving to increase Hansoh Pharma 's brand influence, create excellence in pharmaceuticals and enhance innovation in China while building advantages in R&D, quality, talents and management at the high end of the industry.
